Breaking News

Biodel, Emergent BioSolutions Enter Glucagon Mfg. Pact

By Kristin Brooks | March 6, 2014

To provide fill/finish of commercial quantities for GEM device

Biodel Inc. has signed a long-term manufacturing agreement with Cangene bioPharma Inc., doing business as Emergent BioSolutions, under which Emergent will fill and finish commercial quantities of a GEM device for use with glucagon. Financial terms were not disclosed.
 
Biodel’s GEM device is a customized version of Unilife's dual-chamber auto-reconstitution syringe, and is being developed for use as a rescue treatment for severe hypoglycemia. GEM is designed as an intuitive, easy-to-use device to address currently available kits that are considered difficult to assemble and operate during an emergency.
The fill/finish agreement, along with the previously-announced license and supply agreement for the GEM device with Unilife, and bulk glucagon supply agreement with Bachem, continue the company's preparation for the NDA submission anticipated in 2015 and subsequent commercial launch.
 
Dr. Errol De Souza, Biodel's president and chief executive officer, said, "We are pleased to reach another important milestone as we rapidly advance the commercialization of the first of our two unique glucagon rescue product candidates. We look forward to progressing through increasingly advanced stages of product development."
 

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks